Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Subscribe To Our Newsletter & Stay Updated
